Taking Action on DIR Fees

September 15, 2016 | Jeremy Johnson

This week, four senators (Shelley Moore Capito, R-W.Va., Jon Tester, D-Mont., John Boozman, R-Ark., and Tom Cotton, R-Ark.) introduced bipartisan legislation to prohibit retroactive DIR fees in the “Improving Transparency and Accuracy in Medicare Part D Spending Act.”

NCPA—on behalf of the independent pharmacies it represents—has been a strong advocate for the move: 

“In banning retroactive DIR fees, S. 3308 / H.R. 5951 would improve transparency in Medicare Part D as many members of Congress, Medicare officials and NCPA have urged. The bill would also lower beneficiary cost-sharing at the pharmacy counter without increasing Medicare Part D costs.”

Continue reading →

The Weekly Roundup

August 12, 2016 | Pamela Youngberg Dickson

Six retail chains dominate the 340B market, according to recent research by the Drug Channels Institute. Walgreens, Walmart, CVS, Rite Aid, Kroger, and Albertsons. And, as the author points out, if Walgreen Boots Alliance completes its purchase of RiteAid (and doesn’t divest any pieces of the business) it will have more than 40% of the 340B locations in the country. Are providers using the program properly? No one knows—and guidance has been slow in coming.

Continue reading →